Full text loading...
Diabetic cardiomyopathy (DCM) is a critical complication involving oxidative stress and inflammation, that is not amenable to current therapeutic strategies. Herbal remedies are increasingly being used as an alternative to current treatment options.
In this research, we evaluated the effects of Cinnamomum tamala (Buch.-Ham.) Th. G. G. Nees leaves the extract in DCM and its scope as an adjunct or alternative therapy along with existing standard treatment.
The ethanolic extract was prepared using the Soxhlet apparatus and rotary evaporator. Streptozotocin (1st day) and isoproterenol (12th and 13th day) were given to induce DCM in rats. Oral treatment with ethanolic extract of C. tamala leaves (250 and 500 mg/kg) or glibenclamide (10 mg/kg) was given from the 3rd to the 14th day.
C. tamala extract or glibenclamide attenuated streptozotocin-induced hyperglycemia in rats. C. tamala extract or glibenclamide (10 mg/kg) inhibited serum dyslipidemia, lactate dehydrogenase, and creatine kinase MB activities. The body weight, total heart protein, and heart weight were ameliorated by C. tamala extract or glibenclamide (10 mg/kg). Furthermore, DCM culminated in cardiac oxidative stress and inflammation, and these biochemical parameters were ameliorated by C. tamala extract or glibenclamide (10 mg/kg) treatment. The combination of C. tamala extract (500 mg/kg) and glibenclamide (5 mg/kg, low dose) significantly attenuated DCM relative to separate treatments.
C. tamala can be a useful alternative or adjunct therapy in DCM therapeutics. The combinatorial treatment approach with C. tamala might reduce the dose of therapeutic molecules used in the current clinical practice of DCM.